Profil bibliographique

Rubana N. Kalyani

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

44Publications signalées

1573Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

Regulation of Appetite and ObesityBiochemical Analysis and Sensing TechniquesSystemic Lupus Erythematosus Researchmelanin and skin pigmentationMonoclonal and Polyclonal Antibodies Research

Publications récentes

Accès ouvert 2024 articleOpenAlex

A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale

Dinesh Khanna, Christopher P. Denton, Shervin Assassi, Masataka Kuwana et autres

18 citationsClinical and Experimental Rheumatology

Accès ouvert 2023 erratumOpenAlex

Correction: Plasma protein biomarkers reflective of the host response in patients developing Intensive Care Unit-acquired pneumonia

Tjitske S. R. van Engelen, Tom D. Y. Reijnders, Fleur P. Paling, Marc J. M. Bonten et autres

0 citationsCritical Care

Accès ouvert 2023 articleOpenAlex

Impact of SARS-CoV-2 infection on patients with systemic lupus erythematosus in England prior to vaccination: a retrospective observational cohort study

Adrian Rabe, Wei Jie Loke, Rubana N. Kalyani, Raj Tummala et autres

0 citationsBMJ Open

Accès ouvert 2023 articleOpenAlex

Plasma protein biomarkers reflective of the host response in patients developing Intensive Care Unit-acquired pneumonia

Tjitske S. R. van Engelen, Tom D. Y. Reijnders, Fleur P. Paling, Marc J. M. Bonten et autres

7 citationsCritical Care

Accès ouvert 2022 articleOpenAlex

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

Edward M Vital, Joan T. Merrill, Eric F. Morand, Richard Furie et autres

149 citationsAnnals of the Rheumatic Diseases

Accès ouvert 2022 articleOpenAlex

Inhibition of Serum Lipase as a Mechanism of Action for Anti-Obesity Potentials of Dioscorea bulbifera Extracts on Wistar Rats

Precious Whiskey Ikete, Bruno Chukwuemeka Chinko, Rubana N. Kalyani

5 citationsAsian Journal of Health Sciences

2021 articleOpenAlex

Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus

Richard Furie, Eric F. Morand, Anca Askanase, Edward M Vital et autres

80 citationsLupus

Accès ouvert 2021 articleOpenAlex

Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials

Raj Tummala, Gabriel Abreu, Lilia Pineda, M. Alex Michaels et autres

92 citationsLupus Science & Medicine

Accès ouvert 2020 conference-abstractOpenAlex

OP0049 EFFICACY OF ANIFROLUMAB IN ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: PATIENT SUBGROUP ANALYSIS OF BICLA RESPONSE IN 2 PHASE 3 TRIALS

Eric F. Morand, Richard Furie, Y. Tanaka, Rubana N. Kalyani et autres

9 citationsAnnals of the Rheumatic Diseases

Accès ouvert 2020 conference-abstractOpenAlex

SAT0174 FLARE ASSESSMENTS IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH ANIFROLUMAB IN 2 PHASE 3 TRIALS

Richard Furie, Eric F. Morand, Anca Askanase, Edward M Vital et autres

3 citationsAnnals of the Rheumatic Diseases

Accès ouvert 2020 conference-abstractOpenAlex

OP0003 EARLY AND SUSTAINED RESPONSES WITH ANIFROLUMAB TREATMENT IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN 2 PHASE 3 TRIALS

Eric F. Morand, Richard Furie, Ian N Bruce, Kenneth Kalunian et autres

5 citationsAnnals of the Rheumatic Diseases

Accès ouvert 2020 conference-paperOpenAlex

O24 Flare assessments in patients with active systemic lupus erythematosus (SLE) treated with anifrolumab in 2 phase 3 trials

Richard Furie, Eric F. Morand, Anca Askanase, Edward M Vital et autres

1 citationOral Presentations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.